Exploratory analysis of predictive and prognostic biomarkers in the randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (WJOG4407GTR)
Not Applicable
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000002031
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) To correlate micro vascular density (MVD) and expression of VEGF-A in the tumor specimens with response rates (RR), progression free survival (PFS) and over all survival (OS). 2) To correlate expressions of various genes and k-Ras gene status in the tumor specimens with RR, PFS and OS. 3) To correlate the values of angiogenesis-related growth factors in plasma with RR, PFS and OS. 4) To correlate the profiles of glycoconjugates in plasma with RR, PFS and OS.
- Secondary Outcome Measures
Name Time Method ot applicable